Citius Oncology reports Q2 FY2026 net loss $26.6M; LYMPHIR revenue $1.7M, launch progressing

CITIUS ONCOLOGY, INC.

2026-Q2 EPS reported -$0.34 revenue$5,611,409

Net product revenues $1.7M in Q2 ($5.6M H1) vs $0 prior year; gross margin 80%.
Net loss $26.6M vs $7.7M prior year, driven by $19.7M one-time CMO contract cancellation.
Cash $2.6M at March 31; subsequent $11.5M warrant exercise and $10M debt tranche from Avenue Capital ($25M facility).
83% of target accounts on formulary or in review; near 100% payer coverage; initial European shipment.
Hired Jefferies as exclusive financial advisor to evaluate strategic alternatives; combined cash runway through Nov 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CITIUS ONCOLOGY, INC. reported the fiscal second quarter ended March 31, 2026 results: revenue $1.7 million.

Period: the fiscal second quarter ended March 31, 2026
Revenue: $1.7 million
Result: reported results

Exact text from the filing

revenue milestones; and, ○ approximately $11.5 million in gross proceeds received May 5, 2026 from the exercise of certain outstanding warrants; and, ● Net product revenues of $1.7 million for the three months ended March 31, 2026, compared to no revenue for the three months ended March 31, 2025; and $5.6 million for the six months ended March 31, 2026, compared

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

CITIUS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-057883

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.